Mymetics Corp (MYMX)

[Work Harder]

Sanofi is manufacturing the trispecific antibody for use in a Phase 1 clinical trial that will be conducted by NIAID to test the antibody’s safety and pharmacokinetics in healthy people beginning in late 2018.

Discussions also are under way with the NIAID-funded AIDS Clinical Trials Group to conduct a separate Phase 1 clinical trial of the antibody in people living with HIV.

“The partnership between NIAID and Sanofi has been invaluable and allows us to move this trispecific antibody from the lab and preclinical testing into the clinic,” said John R. Mascola, M.D., director of the NIAID Vaccine Research Center (VRC).

https://www.precisionvaccinations.com/trispecific-hiv-vaccine-candidate-broadly-neutralizes-hiv-antibodies

So what's the Upperton Catalent stuffium for

?